灵活剂量艾司氯胺酮鼻喷剂联合新启抗抑郁药治疗难治性抑郁的疗效与安全性
这项3期双盲活性对照多中心研究纳入227例难治性抑郁成人患者,随机接受灵活剂量艾司氯胺酮鼻喷剂(56或84 mg,每周两次)联合新启抗抑郁药,或新启抗抑郁药联合安慰剂鼻喷剂。第28天MADRS评分较基线的改善在艾司氯胺酮组显著优于对照组(最小二乘均值差=-4.0,SE=1.69,95%CI=-7.31,-0.64),且艾司氯胺酮组不良事件更常见但多在给药后1.5小时内缓解。
要点
- 艾司氯胺酮鼻喷剂联合新启抗抑郁药在第28天MADRS改善显著优于抗抑郁药联合安慰剂。
- 常见不良事件(解离、恶心、眩晕、味觉障碍、头晕)在艾司氯胺酮组更常见,多短暂可缓解。
- 艾司氯胺酮组因不良事件停药比例为7%,对照组为0.9%。
核心结论
- 灵活剂量艾司氯胺酮鼻喷剂联合新启抗抑郁药可快速改善难治性抑郁症状且安全性可接受。
研究设计与样本
- 3期双盲活性对照多中心研究,在39个门诊转诊中心纳入227例中度至重度非精神病性抑郁且对至少两种抗抑郁药无应答的成人患者。
主要发现
- 第28天MADRS评分较基线变化,艾司氯胺酮联合抗抑郁药组显著优于抗抑郁药联合安慰剂组(最小二乘均值差=-4.0,SE=1.69,95%CI=-7.31,-0.64)。
- 艾司氯胺酮联合抗抑郁药组在更早时间点即观察到临床有意义的改善。
- 最常见不良事件为解离、恶心、眩晕、味觉障碍和头晕,均在艾司氯胺酮组更频繁。
- 艾司氯胺酮组7%和对照组0.9%的患者因不良事件停用研究药物。
- 艾司氯胺酮组不良事件一般在给药后不久出现,并在给药后1.5小时内缓解。
关键数值与推荐
- 艾司氯胺酮鼻喷剂剂量为56或84 mg,每周两次。
- 主要疗效终点为第28天MADRS评分较基线的变化。
- 入组标准包括当前发作对至少两种抗抑郁药无应答,其中一种经前瞻性评估。
临床怎么用
- 对于难治性抑郁患者,可考虑艾司氯胺酮鼻喷剂联合新启口服抗抑郁药作为快速起效的治疗选择。
- 给药后需关注解离、恶心、眩晕、味觉障碍和头晕等不良事件,通常1.5小时内缓解。
局限性
- 原文未报告盲法评估细节、长期疗效及耐受性数据。
- 研究仅纳入非精神病性抑郁成人,排除精神病性特征患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active comparator) plus placebo nasal spray. METHODS: This was a phase 3, double-blind, active-controlled, multicenter study conducted at 39 outpatient referral centers. The study enrolled adults with moderate to severe nonpsychotic depression and a history of nonresponse to at least two antidepressants in the current episode, with one antidepressant assessed prospectively. Confirmed nonresponders were randomly assigned to treatment with esketamine nasal spray (56 or 84 mg twice weekly) and an antidepressant or antidepressant and placebo nasal spray. The primary efficacy endpoint, change from baseline to day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) score, was assessed by a mixed-effects model using repeated measures. RESULTS: Of 435 patients screened, 227 underwent randomization and 197 completed the 28-day double-blind treatment phase. Change in MADRS score with esketamine plus antidepressant was significantly greater than with antidepressant plus placebo at day 28 (difference of least square means=-4.0, SE=1.69, 95% CI=-7.31, -0.64); likewise, clinically meaningful improvement was observed in the esketamine plus antidepressant arm at earlier time points. The five most common adverse events (dissociation, nausea, vertigo, dysgeusia, and dizziness) all were observed more frequently in the esketamine plus antidepressant arm than in the antidepressant plus placebo arm; 7% and 0.9% of patients in the respective treatment groups discontinued study drug because of an adverse event. Adverse events in the esketamine plus antidepressant arm generally appeared shortly after dosing and resolved by 1.5 hours after dosing. CONCLUSIONS: Current treatment options for treatment-resistant depression have considerable limitations in terms of efficacy and patient acceptability. Esketamine is expected to address an unmet medical need in this population through its novel mechanism of action and rapid onset of antidepressant efficacy. The study supports the efficacy and safety of esketamine nasal spray as a rapidly acting antidepressant for patients with treatment-resistant depression.
引用
- Popova V, Daly EJ, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. 2019. PMID: 31109201. doi:10.1176/appi.ajp.2019.19020172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。